Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation

Xenotransplantation

Volumn 17, Issue 1, 2010, Pages 26-37

  Miwa, Yuko ^a   Yamamoto, Koji ^a   Onishi, Akira ^b   Iwamoto, Masaki ^b,c   Yazaki, Satoko ^b,c   Haneda, Masataka ^a   Iwasaki, Kenta ^a   Liu, Dage ^a   Ogawa, Haruko ^d   Nagasaka, Takaharu ^e   Uchida, Kazuharu ^e   Nakao, Akimasa ^a   Kadomatsu, Kenji ^a   Kobayashi, Takaaki ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

^c Prime Tech Ltd   (Japan)

^d OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^e NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Coagulation disorder; Decay accelerating factor; Gene transfer; Thrombomodulin; Xenotransplantation

Indexed keywords

ACTIVATED PROTEIN C; BETA GALACTOSIDASE; CD97 ANTIGEN; THROMBIN; THROMBOMODULIN;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD55; AORTA; BLOOD COAGULATION; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; SUS SCROFA; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TRANSPLANTATION, HETEROLOGOUS; WHOLE BLOOD COAGULATION TIME;

EID: 76349087621     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2009.00555.x     Document Type: Article

References (53)

1. Kuwaki K, Tseng Y, Dor F et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005 11 : 29 31.
2. Shimizu A, Hisashi Y, Kuwaki K et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008 172 : 1471 1481.
3. Cozzi E, Bhatti F, Schmoeckel M et al. Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts. Transplantation 2000 70 : 15 21.
4. Sun H, Chen G, Liu W et al. The influence of baseline expression of human decay accelerating factor transgene on graft survival and acute humoral xenograft rejection. Transplantation 2005 80 : 1331 1339.
5. Shimizu A, Yamada K, Yamamoto S et al. Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol 2005 16 : 2732 2745.
6. Van Den Berg C, Rix C, Hanna S et al. Role and regulation of pig CD59 and membrane cofactor protein/CD46 expressed on pig aortic endothelial cells. Transplantation 2000 70 : 667 673.
7. Adams D, Kadner A, Chen R, Farivar R. Human membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from hyperacute rejection in primates. Xenotransplantation 2001 8 : 36 40.
8. Cabric S, Sanchez J, Lundgren T et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007 56 : 2008 2015.
9. Kopp C, Siegel J, Hancock W et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997 63 : 749 758.
10. Chen D, Riesbeck K, Kemball-Cook G et al. Inhibition of tissue factor-dependent and -independent coagulation by cell surface expression of novel anticoagulant fusion proteins. Transplantation 1999 67 : 467 474.
11. Lee K, Salvaris E, Roussel J et al. Recombinant pig TFPI efficiently regulates human tissue factor pathways. Xenotransplantation 2008 15 : 191 197.
12. Siegel J, Grey S, Lesnikoski B et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997 64 : 888 896.
13. Kopp C, Grey S, Siegel J et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells. Transplantation 1998 66 : 244 251.
14. Roussel J, Moran C, Salvaris E et al. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008 8 : 1101 1112.
15. Suzuki K, Stenflo J, Dahlbäck B, Teodorsson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983 258 : 1914 1920.
16. Fulcher C, Gardiner J, Griffin J, Zimmerman T. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984 63 : 486 489.
17. Isermann B, Vinnikov I, Madhusudhan T et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007 13 : 1349 1358.
18. Bernard G, Vincent J, Laterre P et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 : 699 709. (Pubitemid 32204987)
19. Jurd K, Gibbs R, Hunt B. Activation of human prothrombin by porcine aortic endothelial cells - a potential barrier to pig to human xenotransplantation. Blood Coagul Fibrinolysis 1996 7 : 336 343.
20. Chan C, Chan M, Liu M et al. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity. J Immunol 2002 168 : 5170 5177.
21. Ghanekar A, Mendicino M, Liu H et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 2004 172 : 5693 5701.
22. Saadi S, Holzknecht R, Patte C, Stern D, Platt J. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995 182 : 1807 1814.
23. Huber-Lang M, Sarma J, Zetoune F et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006 12 : 682 687.
24. Muhlfelder T, Niemetz J, Kreutzer D et al. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest 1979 63 : 147 150.
25. Krarup A, Wallis R, Presanis J, Gál P, Sim R. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE 2007 2 : e623.
26. Rittirsch D, Flierl M, Ward P. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008 8 : 776 787.
27. Kuwaki K, Knosalla C, Dor F et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004 4 : 363 372.
28. Mcgregor C, Davies W, Oi K et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005 130 : 844 851.
29. Brandl U, Jöckle H, Erhardt M et al. Reduced fibrin deposition and intravascular thrombosis in hDAF transgenic pig hearts perfused with tirofiban. Transplantation 2007 84 : 1667 1676.
30. Ogawa H, Muramatsu H, Kobayashi T et al. Molecular cloning of endo-beta-galactosidase C and its application in removing alpha-galactosyl xenoantigen from blood vessels in the pig kidney. J Biol Chem 2000 275 : 19368 19374.
31. Liu D, Kobayashi T, Yokoyama I et al. Enzymatic removal of alphaGal antigen in pig kidneys by ex vivo and in vivo administration of endo-beta-galactosidase C. Xenotransplantation 2002 9 : 228 236.
32. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991 108 : 193 199.
33. Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001 25 : 402 408.
34. Elisen M, Von Dem Borne P, Bouma B, Meijers J. Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma. Blood 1998 91 : 1542 1547.
35. Nagasaka T, Kobayashi T, Muramatsu H et al. alpha-Galactosyl oligosaccharides conjugated with polyethylene glycol as potential inhibitors of hyperacute rejection upon xenotransplantation. Biochem Biophys Res Commun 1997 232 : 731 736.
36. Huang C, Ives H. Growth inhibition by protein kinase C late in mitogenesis. Nature 1987 329 : 849 850.
37. Coughlin S. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999 96 : 11023 11027.
38. Shuman M. Thrombin-cellular interactions. Ann N Y Acad Sci 1986 485 : 228 239.
39. Conway E, Rosenberg R. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988 8 : 5588 5592.
40. Lentz S, Tsiang M, Sadler J. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991 77 : 542 550.
41. Esmon C, Esmon N, Harris K. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 1982 257 : 7944 7947.
42. Esmon N, Carroll R, Esmon C. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983 258 : 12238 12242.
43. Conway E, Van De Wouwer M, Pollefeyt S et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002 196 : 565 577.
44. Abeyama K, Stern D, Ito Y et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti inflammatory mechanism. J Clin Invest 2005 115 : 1267 1274.
45. Hamilton K, Hattori R, Esmon C, Sims P. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990 265 : 3809 3814.
46. Liu D, Kobayashi T, Onishi A et al. Relation between human decay-accelerating factor (hDAF) expression in pig cells and inhibition of human serum anti-pig cytotoxicity: value of highly expressed hDAF for xenotransplantation. Xenotransplantation 2007 14 : 67 73.
47. Cowan P, Aminian A, Barlow H et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002 2 : 520 525.
48. Cozzi E, Simioni P, Boldrin M et al. Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts. Transplantation 2005 80 : 1501 1510.
49. Ramackers W, Friedrich L, Tiede A et al. Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. Xenotransplantation 2008 15 : 46 55.
50. Chen D, Weber M, Mcvey J et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004 4 : 1958 1963.
51. Ayares D, Phelps C, Vaught T, Ball S. Genetic engineering of pigs improved transplant outcomes. Xenotransplantation 2007 14 : 428.
52. Salvaris E, Harrison S, Beebe L et al. Generation of Gal knockout pig expressing human CD39. Xenotransplantation 2007 14 : 417 418.
53. Saito H, Maruyama I, Shimazaki S et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007 5 : 31 41.